Key Highlights

  • Global net product revenues reached $1.292 billion in Q3 2026, a 52% increase compared with Q3 2025.
  • Total TTR revenues — spanning AMVUTTRA and ONPATTRO — grew 59% year-over-year to $1.150 billion.
  • TRITON-CM Phase 3 study for nucresiran expanded enrollment target from 1,750 to approximately 2,250 patients.
  • Phase 1 data for brezosiran in Huntington's disease showed mean CSF mHTT reductions of 60-64% in the highest dose group.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported consolidated global net product revenues of $1.292 billion for the third quarter ended September 30, 2026, a 52% increase compared with the same period in 2025. The Cambridge, Massachusetts-based RNAi therapeutics company attributed the growth primarily to its TTR franchise, which generated $1.150 billion in combined revenues from AMVUTTRA (vutrisiran) and ONPATTRO (patisiran), representing a 59% year-over-year increase.

TTR Franchise Continues to Expand

AMVUTTRA generated $1.130 billion in global net product revenues during the quarter, while ONPATTRO contributed $20 million. U.S. TTR net product revenues increased $99 million compared with Q2 2026, with the growth driven by an $81 million increase in demand, a $17 million inventory benefit, and a modest increase in net price aided by approximately $10 million in favorable gross-to-net adjustments. International TTR revenues rose $20 million from the prior quarter, supported by ongoing ATTR-CM launches in Japan, Germany and Italy, as well as order timing in partner markets.

The Rare product segment, comprising GIVLAARI (givosiran) and OXLUMO (lumasiran), generated combined revenues of $142 million in Q3 2026, a 12% increase compared with Q3 2025. GIVLAARI contributed $89 million and OXLUMO $53 million to the quarter's total.

TRITON-CM Enrollment Expanded, Nucresiran Timeline Intact

Alnylam announced an update to the TRITON-CM Phase 3 study of nucresiran, an investigational next-generation RNAi therapeutic for ATTR cardiomyopathy. The company expanded the target enrollment from 1,750 to approximately 2,250 patients. Management stated that the expansion is enriched for patients with early disease, who are expected to experience greater benefit, and is designed to ensure adequate study power given conservative estimates of outcome event rates. The company maintained its expectation to launch nucresiran in ATTR-CM by 2030, assuming positive data and regulatory approval.

Brezosiran Phase 1 Data and Pipeline Updates

Alnylam also reported initial Phase 1 data for brezosiran (ALN-HTT02), an investigational RNAi therapeutic for Huntington's disease developed in collaboration with Regeneron Pharmaceuticals. In the highest dose group evaluated, patients experienced mean reductions in cerebrospinal fluid mutant huntingtin protein of 60-64% from baseline at month three, with a maximum individual reduction of 83%. The safety and tolerability profile was described as encouraging, with no dose-dependent increases in inflammatory markers or neurofilament light chain observed. The company plans to initiate a placebo-controlled pivotal study in 2027 pending regulatory alignment.

Alnylam also advanced mivelsiran, an APP-targeting RNAi therapeutic for cerebral amyloid angiopathy and Alzheimer's disease, completing enrollment in the cAPPricorn-1 Phase 2 study and initiating a Phase 2 trial in Down syndrome-associated Alzheimer's disease. The company confirmed it remains on track to achieve its full-year 2026 financial guidance. Additional pipeline readouts are expected at the AHA Scientific Sessions in November 2026 and at the ASH Annual Meeting in December 2026, with the PDUFA date for cemdisiran in myasthenia gravis also expected in November 2026.